Pharmaceuticals

Jazz Pharma

UBS Upgrades Jazz Pharma to Buy, Raises Price Target to $307

Jazz Pharma released FY2026 Q1 earnings on May 5 After-Market EST, actual revenue USD 1.069 B (forecast USD 979.01 M), actual EPS USD 4.43 (forecast USD 1.828)

Jazz Pharma to release FY2026 Q1 earnings report on May 5 After-Market EST, forecast revenue USD 982.74 M, EPS USD 1.9352

Jazz Pharma Announces FDA's Priority Review of Ziihera® Supplemental BLA for HER2+ Gastric or GEJ Cancer

Jazz Pharma released FY2025 Q4 earnings on February 24 After-Market EST, actual revenue USD 1.198 B (forecast USD 1.165 B), actual EPS USD 3.2071 (forecast USD 2.8929)

Jazz Pharma released FY2025 annual earnings on February 24 After-Market (EST), actual revenue USD 4.268 B (forecast USD 4.239 B), actual EPS USD -5.8403 (forecast USD -6.1738)

Jazz Pharma to release FY2025 Q4 earnings on February 24 After-Market EST, forecast revenue USD 1.165 B, EPS USD 2.8929

Jazz Pharmaceuticals Acquires Chimerix and Incorporates into Its Strategy

Analysts Upgrade Jazz Pharmaceuticals Ratings and Target Price

Needham Maintains Jazz Pharmaceuticals Buy Rating With $210 Price Target

Jazz Pharmaceuticals Announces Positive Results of Ziihera Phase III Clinical Trial for HER2-Positive Metastatic Gastroesophageal Adenocarcinoma

Jazz Pharma to Hold Investor Webcast on Zanidatamab Phase 3 Trial Results

Jazz Pharmaceuticals Reports Positive Clinical Updates for Epidiolex and Ziihera

Jazz Pharmaceuticals' VP and CAO Patricia Carr Sells Shares

Jazz Pharmaceuticals' Senior Vice President Disposes of Common Stock

Jazz Pharmaceuticals Displays Xywav® Efficacy Data for Treating Narcolepsy

Schroder Investment Management Group Increased Holdings in Jazz Pharmaceuticals by 90.1%

Jazz Pharma to Present New Treatment Data on Epidiolex® at AAN Annual Meeting

Jazz Pharmaceuticals Director O'Keefe Sold 603 Shares of Company Stock

Jazz Pharmaceuticals to Present Ziihera® Phase 3 Trial Results at ASCO GI 2026

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

JAZZ

LABU

SBIO

IBBQ

Tredje AP fonden acquired 43,200 shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) valued at approximately $7.34 million in Q4, according to a recent SEC filing. Other institutional investors have also increased their stakes, with Dimensional Fund Advisors boosting holdings by 11.8%. Analysts have given Jazz Pharmaceuticals a 'Moderate Buy' rating, with an average target price of $238.00.

Market Beat

SPDR S&P Biotech

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

VG Health

Invesco Nasdaq Biotechnology ETF

Zymeworks

Ameriprise Financial

JPMorgan Chase

Raymond James Financial

Barclays

Toronto Dominion Bank

ROYAL BANK OF CANADA

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

RAYMOND JAMES FINANCIAL INC 6.375%DEP SHS REP 1/40TH FXD FLTG SER B

43,200 Shares in Jazz Pharmaceuticals PLC $JAZZ Bought by Tredje AP fonden

ALKS

Alkermes has achieved a significant milestone with its $2.37 billion acquisition of Avadel, as the phase 3 study of Lumryz for idiopathic hypersomnia met all primary and secondary endpoints. This positive outcome allows Alkermes to plan for FDA approval by the end of 2026, with a potential launch in early 2028. Lumryz aims to compete with Jazz Pharmaceuticals' Xywav, the only FDA-approved treatment for this condition. Alkermes anticipates Lumryz could generate sales between $350 million and $370 million in its first year.

Fiercepharma

Alkermes

Avadel Pharma

Alkermes’ Lumryz, from $2.4B Avadel buy, hits phase 3 mark in IH

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced its participation in upcoming investor conferences, including the RBC Global Healthcare Conference on May 19, 2026, the Cowen 7th Annual Oncology Innovation Summit on May 27, 2026, and the Jefferies Global Healthcare Conference on June 3, 2026. Audio webcasts of the fireside chats will be available on the company's website, with replays archived for 30 days. Jazz Pharmaceuticals focuses on developing life-changing medicines for rare diseases and is headquartered in Dublin, Ireland.

StockTitan

Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences | JAZZ Stock News

HOWL

ARKG

Werewolf Therapeutics Inc. reported a Q1 2026 net loss of $13.53 million, improving from a loss of $18.09 million in Q1 2025. R&D expenses decreased to $8.18 million from $13.12 million. The company has $46.50 million in cash and equivalents. Additionally, Werewolf entered an asset purchase agreement with Jazz Pharmaceuticals for global rights to JZP898. The stock closed at $0.62, down 4.64%.

nasdaq

Werewolf Therapeutics

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

Nasdaq

Werewolf Reports Q1 Loss Of $13 Mln, Highlights Asset Purchase Agreement With Jazz

Jazz Pharmaceuticals (JAZZ) reported Q1 2026 revenue of $1.1 billion and basic EPS of $4.74, rebounding from a challenging previous year. Despite a trailing profit margin of 0.7% due to a $1.5 billion one-off loss, recent quarterly profits suggest stronger earnings potential. Critics highlight concerns over margin pressure and debt costs, while supporters argue that recent EPS growth indicates a more favorable outlook. The stock trades at a P/S of 3.2x, below industry averages, with analysts projecting revenue growth of 7.1% and earnings growth of 28.6% over the next three years.

Simplywall

Jazz Pharmaceuticals (JAZZ) Q1 EPS Rebound Tests Bearish Margin Narratives

Jazz Pharmaceuticals reported record Q1 2026 revenue of $1.07 billion, driven by a 45% growth in its oncology portfolio. Key products include Zebselka, which saw a 60% sales increase, and Modezo, achieving $41 million in net sales. The company anticipates strong future growth with the potential approval of zanadatamab, supported by promising clinical trial data. Jazz reaffirmed its 2026 revenue guidance of $4.25 to $4.5 billion, despite increased competition in the sleep business. The balance sheet remains robust with $2.9 billion in cash, allowing for continued R&D investments and potential acquisitions.

benzinga_article

iShares US Pharma

Jazz Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript

UL Solutions shares are trading higher after the company reported better-than-expected Q1 financial results.

UL Solutions

Jazz Pharma(JAZZ.US)